31 results
SC TO-C
EX-99.3
ETTX
Entasis Therapeutics Holdings Inc.
23 May 22
Information about tender offer
8:54pm
disease as a great opportunity for two reason:
First, anti-infectives innovation is one of the most important priorities for global health and societal
SC TO-C
EX-99.1
ETTX
Entasis Therapeutics Holdings Inc.
23 May 22
Information about tender offer
8:54pm
with significant unmet medical need. Innoviva shares your belief in novel infectious disease therapies as a critical area of innovation and value to patients
8-K
EX-99.1
INVA
Innoviva Inc
22 Apr 14
Breo™Ellipta® (fluticasone furoate/vilanterol trifenatate) approved in Australia for Asthma and Chronic Obstructive Pulmonary Disease
12:00am
.
“We are delighted that Breo Ellipta is now approved in Australia. GSK is committed to supporting innovation in respiratory medicine and has a strong
SC TO-C
EX-99.2
ETTX
Entasis Therapeutics Holdings Inc.
23 May 22
Information about tender offer
8:54pm
-infectives innovation is a critical priority for societal health as well an area with significant value creation potentialWe are excited about the progress
8-K
EX-99.2
INVA
Innoviva Inc
1 Dec 14
Anoro® Ellipta® (umeclidinium/vilanterol) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
12:00am
and affordable to our Australian patients.
“The listing of Breo Ellipta reinforces GSK’s commitment to innovation in respiratory health and we are proud
8-K
EX-99.1
g8auf8gyewht7xuyo2y
13 Dec 21
Corporate Presentation December 2021
4:39pm
8-K
EX-99.1
abkld j8kre45
7 Apr 22
Regulation FD Disclosure
5:09pm
8-K
EX-99.1
rdt9rfyjmuhhp2v
24 May 23
Corporate Presentation May 2023
5:18pm
8-K
EX-99.1
swtc77gjg0n11sy0
23 Aug 22
Other Events
4:08pm